6533b855fe1ef96bd12b131e

RESEARCH PRODUCT

Local excision for more advanced rectal tumors

Werner KneistTheodor JungingerInes GockelThomas Borschitz

subject

AdultMaleReoperationLocal excisionmedicine.medical_specialtyColorectal cancermedicine.medical_treatmentRectal TumorsmedicineAdjuvant therapyHumansRadiology Nuclear Medicine and imagingDigestive System Surgical ProceduresAgedNeoplasm StagingR0 resectionRectal Neoplasmsbusiness.industryCarcinomaHematologyGeneral MedicineMiddle Agedmedicine.diseaseNeoadjuvant TherapySurgeryOncologyChemotherapy AdjuvantFemaleRadiotherapy AdjuvantbusinessAdjuvantFollow-Up StudiesNeoadjuvant chemoradiotherapy

description

Over the past 20 years, local excision (LE) of T1 rectal cancer was increasingly established and represents an oncologically established technique. In contrast, the situation for T2 tumors is less clear and has only been investigated in small patient collectives. LE for T2 tumors is thus discussed controversially.In addition to our own patients with T2 rectal cancer treated locally (n=40), we have analysed the local recurrence (LR) rates after LE alone (n=124), after immediate conventional radical reoperation (n=29), after adjuvant (chemo)-radiotherapy (n=294) and those after neoadjuvant chemoradiotherapy (nCRT) (n=269) using a PubMed search.LR rates of low-grade T2 tumors after R0 resection by LE alone was 19%. If additional prognostically unfavorable findings were present, the LR rate rose to 52%. By immediate radical reoperation the LR rate was decreased to 7%, whereas that after adjuvant therapy was 16%. In contrast, LE of more advanced tumors after nCRT resulted in LR rates of 9%.LE alone of T2 rectal cancer should not be performed, and after adjuvant chemoradiotherapy the risk of developing LR was also high. In cases with unexpected T2 finding after LE, immediate conventional reoperation can represent an adequate oncological therapy, because it reveals comparable results to those obtained by primary radical resection. First results after nCRT followed by LE showed favorable results with low LR rates. If the indication for LE of T2 cancers can be extended to patients after nCRT in the future will have to be determined in prospective mutlticentre studies.

https://doi.org/10.1080/02841860701829653